Research Analysts Issue Forecasts for argenx SE’s Q1 2025 Earnings (NASDAQ:ARGX)

argenx SE (NASDAQ:ARGX) – Analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of argenx in a report released on Wednesday, June 26th. HC Wainwright analyst D. Tsao expects that the company will earn $0.16 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $448.00 target price on the stock. The consensus estimate for argenx’s current full-year earnings is ($2.88) per share. HC Wainwright also issued estimates for argenx’s Q2 2025 earnings at $0.72 EPS, Q3 2025 earnings at $1.19 EPS and Q4 2025 earnings at $0.64 EPS.

Several other analysts also recently issued reports on ARGX. Piper Sandler raised their price objective on shares of argenx from $522.00 to $535.00 and gave the stock an “overweight” rating in a research note on Monday, June 24th. Wedbush reissued an “outperform” rating and set a $519.00 price target on shares of argenx in a research note on Wednesday. JMP Securities cut their price objective on argenx from $471.00 to $468.00 and set a “market outperform” rating on the stock in a research report on Friday, May 10th. Robert W. Baird decreased their target price on argenx from $505.00 to $490.00 and set an “outperform” rating for the company in a research report on Friday, March 1st. Finally, Morgan Stanley lowered their target price on shares of argenx from $515.00 to $510.00 and set an “overweight” rating for the company in a research note on Tuesday, May 28th. Five equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $525.42.

argenx Trading Down 3.3 %

ARGX stock opened at $430.04 on Thursday. The stock has a market cap of $25.56 billion, a PE ratio of -75.98 and a beta of 0.65. argenx has a 12 month low of $327.73 and a 12 month high of $550.76. The company has a 50-day moving average price of $382.97 and a 200 day moving average price of $387.13.

argenx (NASDAQ:ARGX) last posted its quarterly earnings data on Monday, May 13th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.33). argenx had a negative return on equity of 14.14% and a negative net margin of 22.58%. The firm had revenue of $412.51 million for the quarter, compared to analysts’ expectations of $404.03 million. During the same period in the previous year, the firm earned ($0.52) earnings per share.

Institutional Investors Weigh In On argenx

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Parkside Financial Bank & Trust purchased a new stake in shares of argenx during the third quarter worth about $28,000. GAMMA Investing LLC raised its position in argenx by 420.0% during the 1st quarter. GAMMA Investing LLC now owns 78 shares of the company’s stock worth $31,000 after buying an additional 63 shares during the last quarter. FNY Investment Advisers LLC purchased a new position in argenx during the 4th quarter worth approximately $38,000. Mather Group LLC. purchased a new position in argenx during the 1st quarter worth approximately $38,000. Finally, Benjamin F. Edwards & Company Inc. purchased a new position in argenx during the 4th quarter worth approximately $60,000. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.